南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

NDUFA9的线粒体SUMO化触发ClpP依赖性降解,并导致线粒体复合体I功能障碍,这与Leigh综合征相关突变密切相关。

Mitochondrial SUMOylation of NDUFA9 drives ClpP-dependent degradation and complex I dysfunction in a Leigh syndrome–associated mutation

Feng Jiaqian, Kang Xueran, Li Xinyue, Wang Xiao-dong, Qiu Yi, Pan Si-Jian, Li Yong

Journal:Nature Communications

IF:18.1

DOI:10.1038/s41467-026-76997-0

PMID:

Published:2026-08-24

research field:农学土壤学代谢组学微生物学植物病理学

Abstract

Mitochondrial complex I (CI) dysfunction causes many inherited mitochondrial diseases, including Leigh syndrome, yet how post-translational modifications control CI subunit proteostasis remains unclear. Here we identify NDUFA9 as a mitochondrial SUMOylation substrate. SUMO1 conjugation at Lys370 promotes NDUFA9 binding to ClpP through the SIM motifs of ClpP and accelerates ClpP-dependent degradation. This destabilizes NDUFA9, reduces fully assembled CI and CI activity, and impairs mitochondrial bioenergetics. Mitochondrial SENP2 counteracts this process, defining a SUMO–SENP2–ClpP axis that preserves NDUFA9 and CI integrity. The Leigh syndrome–associated NDUFA9 R321P mutation enhances Ubc9 binding, increases Lys370 SUMOylation, and drives excessive ClpP-dependent degradation. Preventing SUMOylation with the K370R substitution restores NDUFA9 abundance, CI integrity, and mitochondrial function. In systemic and brain-specific AAV replacement models, blocking SUMOylation also alleviates R321P-induced CI deficiency and motor dysfunction. These findings reveal aberrant NDUFA9 SUMOylation as a pathogenic mechanism in mitochondrial disease.

本文使用的Yeasen产品

购物车
客服
转染试用